HealthPolitics

STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 12/11/2026, 16:36:24 UTC.

Briefings

STAT+ reports Bristol Myers Squibb restructured its R&D leadership, appointing Cristian Massacesi as head of R&D while Robert Plenge departed in March. The article also notes the FDA shelved the Commissioner's National Priority Voucher program and highlights the Senate health committee's upcoming vote on Heidi Overton's nomination, which faces uncertainty due to potential Republican defections.

Key points

• Bristol Myers Squibb appointed Cristian Massacesi as head of R&D and Robert Plenge departed in March.
• The FDA shelved the Commissioner's National Priority Voucher program.

Context

STAT+ provides biotech industry updates and political developments affecting pharmaceuticals, including leadership changes at Bristol Myers Squibb and FDA nominations.

Limitations

Evidence is limited to a single article snapshot from November 2026. No additional background on the impact of these changes is supplied. The article does not contain specific dates beyond the March departure, and the Senate vote outcome remains uncertain.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 12/11/2026, 17:19:55 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeielx2vev2xlfhgdqlmxo2nlr4uamgoqelyzowko2akpct2fjz6lgu